AR101256A1 - Composición vacunal que comprende ipv y ciclodextrinas - Google Patents
Composición vacunal que comprende ipv y ciclodextrinasInfo
- Publication number
- AR101256A1 AR101256A1 ARP150102293A ARP150102293A AR101256A1 AR 101256 A1 AR101256 A1 AR 101256A1 AR P150102293 A ARP150102293 A AR P150102293A AR P150102293 A ARP150102293 A AR P150102293A AR 101256 A1 AR101256 A1 AR 101256A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclodextrin
- ipv
- composition
- antigen
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 2
- 229960004906 thiomersal Drugs 0.000 abstract 2
- -1 2-hydroxypropyl g-cyclodextrin Chemical compound 0.000 abstract 1
- 241000991587 Enterovirus C Species 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 208000000474 Poliomyelitis Diseases 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 1
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composición inmunogénica que comprende al menos un serotipo del poliovirus inactivado (IPV) y al menos una ciclodextrina o derivado de la misma, especialmente b-ciclodextrina, g-ciclodextrina o 2-hidroxipropil g-ciclodextrina, y antígenos adicionales, dicha composición está protegida contra la pérdida del título IPV inducida por tiomersal. Composición inmunogénica para su uso como una vacuna así como también el uso de una ciclodextrina, o un derivado de la misma para preservar la inmunogenicidad a la IPV en presencia de tiomersal. Método para preparar una composición vacunal y método para inmunizar un huésped contra la poliomielitis. Reivindicación 3: La composición de acuerdo con cualquiera de la reivindicación 1 y 2, en donde dicha composición comprende uno o más antígenos adicionales, preferentemente seleccionados del grupo que comprende toxoide diftérico, toxoide tetánico, antígeno Pertussis, antígeno Neisseria meningitidis, antígeno de superficie de la hepatitis B y antígeno Haemophilus influenzae b (Hib).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306179 | 2014-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101256A1 true AR101256A1 (es) | 2016-12-07 |
Family
ID=51263343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102293A AR101256A1 (es) | 2014-07-21 | 2015-07-20 | Composición vacunal que comprende ipv y ciclodextrinas |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR101256A1 (es) |
| WO (1) | WO2016012385A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015163488A1 (en) | 2014-04-25 | 2015-10-29 | Ajinomoto Co., Inc. | Immunostimulating agent |
| EP3511318A1 (en) | 2015-10-28 | 2019-07-17 | Ajinomoto Co., Inc. | Immunostimulating agent |
| CN112516325B (zh) * | 2019-09-18 | 2023-12-08 | 洛阳赛威生物科技有限公司 | 一种稳定的口蹄疫疫苗组合物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4525349A (en) | 1981-12-29 | 1985-06-25 | Societe Anonyme Dite: Institut Merueux | Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| JP3626996B2 (ja) | 1992-05-23 | 2005-03-09 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| BR9710460A (pt) | 1996-07-02 | 1999-08-17 | Connaught Lab | Composi-Æo imunolÄgica multi-valente e seu uso em vacinas |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| DK1556477T3 (en) * | 2002-11-01 | 2017-10-23 | Glaxosmithkline Biologicals Sa | Process for drying |
| EP2491947A3 (en) | 2006-09-07 | 2012-10-17 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| WO2012028315A1 (en) | 2010-09-02 | 2012-03-08 | Sanofi Pasteur Sa | A stabilizer for the preparation of a dry polio injectable vaccine composition |
-
2015
- 2015-07-20 AR ARP150102293A patent/AR101256A1/es unknown
- 2015-07-20 WO PCT/EP2015/066511 patent/WO2016012385A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016012385A1 (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37811A (es) | Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma | |
| WO2012093406A3 (en) | A combination heptavalent vaccine | |
| EP4494650A3 (en) | Vaccine compositions having improved stability and immunogenicity | |
| PH12017500727A1 (en) | Modified virus-like particles of cmv | |
| WO2008112344A3 (en) | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins | |
| WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
| BRPI0607551A2 (pt) | vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso | |
| CO6430434A2 (es) | Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas | |
| AR092896A1 (es) | Composiciones inmunogenicas | |
| BR112012033767A2 (pt) | processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina. | |
| MX346625B (es) | Mutantes de virus de influenza y usos para los mismos. | |
| AR101256A1 (es) | Composición vacunal que comprende ipv y ciclodextrinas | |
| GEP20247684B (en) | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same | |
| MX2018010920A (es) | Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos. | |
| MX2024006589A (es) | Formulaciones de vacunas contra el coronavirus. | |
| AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
| CU20190013A7 (es) | Composiciones de vacunas multivalentes | |
| MX2024003337A (es) | Composiciones inmunogenicas contra la influenza. | |
| WO2011074006A3 (en) | Vaccine composition | |
| WO2016120596A8 (en) | Multi-epitopic construct | |
| ZA202213407B (en) | Compositions and methods of manufacturing trivalent filovirus vaccines | |
| MX2023011129A (es) | Mutantes del virus de la influenza b y usos de los mismos. | |
| BR112016029513A2 (pt) | vacina; processo para a preparação de uma vacina; e método para vacinar um animal não humano | |
| AR108664A1 (es) | Vacuna contra la bronquitis infecciosa | |
| WO2015118473A3 (en) | A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |